

**SHBP PDC RESOLUTION 2025-3**

**RESOLUTION OF THE STATE HEALTH BENEFITS PROGRAM PLAN DESIGN  
COMMITTEE TO REDUCE THE RETIREE PRESCRIPTION DRUG COPAYMENT  
FOR EGWP SPECIALTY MEDICATION**

WHEREAS, pursuant to N.J.S.A. 52:14-17.29 to -17.46a, the State Health Benefits Program (SHBP) provides health coverage to qualified employees and retirees of the State and participating local employers; and

WHEREAS, the SHBP was enacted in 1961 for the purpose of providing affordable health care coverage for public employees on a cost-effective basis; and

WHEREAS, pursuant to N.J.S.A. 52:14-17.28, the State Health Benefits Commission contracts with carriers to provide the State Health Benefit Program (SHBP) to eligible participants; and

WHEREAS, all SHBP plans, with the exception of Medicare Advantage plans, are self-funded, which means that the money paid out for benefits comes directly from a SHBP fund supplied by the State, participating local employers, and member premiums; and

WHEREAS, the SHBP Plan Design Committee recognizes that pharmaceuticals, an integral part of medical treatment, keep patients healthier and extend or save lives and in many situations, proper pharmaceutical use is documented to save money by avoiding costly hospitalization, emergency room use, moving to a nursing home or repeat visits to specialists; and

WHEREAS, the SHBP Plan Design Committee recognizes the Center for Medicare and Medicaid Services (CMS) PY 2023 criteria for the Employer Group Waiver Plan (EGWP) specialty tier as drugs that exceed the \$800 threshold for a 30-day supply; and

WHEREAS, on October 30, 2019, the SHBP Plan Design Committee adopted Resolution 2019-13, which reduced the member cost share for those drugs identified as specialty, by way of price or class of drugs; and

WHEREAS, on August 31, 2020, the SHBP Plan Design Committee adopted Resolution 2020-6, which extended Resolution 2019-13 for one year; and

WHEREAS, on July 26, 2023, the SHBP Plan Design Committee adopted Resolution 2023-2, which extended Resolution 2019-13 for Plan Year 2023; and

WHEREAS, on July 24, 2024, the SHBP Plan Design Committee adopted Resolution 2024-1, which extended Resolution 2019-13 for Plan Year 2025; and

WHEREAS, pursuant to N.J.S.A. 52:14-17.29(D), the SHBP Plan Design Committee finds it in the best interest of the State, local employers, and employees to continue the reduced member cost share for those drugs identified as specialty, by way of price or class of drugs.

NOW THEREFORE, BE IT RESOLVED AS FOLLOWS:

1. Effective January 1, 2025, the 30-day copayments for Specialty Pharmacy in the Employer Group Waiver Plan (EGWP) shall be as follows:

2025-3 EGWP

	Aetna MA PPO ESA 10	Aetna MA PPO ESA 15			Aetna MA Open Access HMO	Aetna MA Open Access HMO 1525	
			Horizon NJ DIRECT 1525	Horizon NJ DIRECT 2030	Horizon HMO	Horizon HMO 1525	Horizon HMO 2030
Mail: Generic Copayments	\$1	\$1	\$1	\$1	\$1	\$1	\$1
Mail: Preferred Brand Copayments	\$9	\$9	\$13	\$12	\$6	\$13	\$12
Mail: Non-Preferred Brand Copayments	\$18	\$18	\$29	\$30	\$10	\$29	\$30

2. These provisions shall continue for one plan year and will continue thereafter only by an affirmative majority vote of the Committee.

DATED: August 27, 2025